Cargando…
The Histone Deacetylase Inhibitor Romidepsin Spares Normal Tissues While Acting as an Effective Radiosensitizer in Bladder Tumors in Vivo
PURPOSE: Muscle-invasive bladder cancer has a 40% to 60% 5-year survival rate with radical treatment by surgical removal of the bladder or radiation therapy–based bladder preservation techniques, including concurrent chemoradiation. Elderly patients cannot tolerate current chemoradiation therapy reg...
Autores principales: | Paillas, Salome, Then, Chee K., Kilgas, Susan, Ruan, Jia-Ling, Thompson, James, Elliott, Amy, Smart, Sean, Kiltie, Anne E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier, Inc
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7181176/ https://www.ncbi.nlm.nih.gov/pubmed/31987970 http://dx.doi.org/10.1016/j.ijrobp.2020.01.015 |
Ejemplares similares
-
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
por: Conforti, Franco, et al.
Publicado: (2017) -
Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin
por: Sager, Philip T, et al.
Publicado: (2015) -
Use of class I histone deacetylase inhibitor romidepsin in combination regimens
por: Petrich, Adam, et al.
Publicado: (2016) -
Chromobacterium spp. mediate their anti-Plasmodium activity through secretion of the histone deacetylase inhibitor romidepsin
por: Saraiva, Raúl G., et al.
Publicado: (2018) -
Association of Bacteroides acidifaciens relative abundance with high-fibre diet-associated radiosensitisation
por: Then, Chee Kin, et al.
Publicado: (2020)